Atticus Wealth Management LLC increased its position in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 89.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 297 shares of the medical research company’s stock after purchasing an additional 140 shares during the period. Atticus Wealth Management LLC’s holdings in Amgen were worth $72,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BlackRock Inc. raised its position in Amgen by 2.1% in the fourth quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company’s stock worth $11,258,926,000 after acquiring an additional 1,032,929 shares during the period. Vanguard Group Inc. grew its stake in shares of Amgen by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 47,329,045 shares of the medical research company’s stock worth $11,445,110,000 after acquiring an additional 668,036 shares during the period. State Street Corp increased its holdings in Amgen by 1.2% in the 1st quarter. State Street Corp now owns 30,504,420 shares of the medical research company’s stock worth $7,376,579,000 after acquiring an additional 357,413 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Amgen by 1.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after purchasing an additional 94,565 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in Amgen by 8.7% in the 4th quarter. Deutsche Bank AG now owns 5,660,218 shares of the medical research company’s stock valued at $1,273,380,000 after buying an additional 453,750 shares in the last quarter. Institutional investors own 77.14% of the company’s stock.
Amgen Trading Down 1.4 %
Shares of AMGN opened at $224.46 on Thursday. The firm has a 50 day moving average price of $243.76 and a 200-day moving average price of $243.39. Amgen Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $258.45. The firm has a market cap of $120.07 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 1.86 and a beta of 0.56. The company has a debt-to-equity ratio of 14.76, a quick ratio of 1.17 and a current ratio of 1.53.
Amgen Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Thursday, August 18th were given a dividend of $1.94 per share. The ex-dividend date was Wednesday, August 17th. This represents a $7.76 annualized dividend and a yield of 3.46%. Amgen’s payout ratio is currently 65.76%.
Insiders Place Their Bets
In related news, Director R Sanders Williams sold 200 shares of the business’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $249.96, for a total transaction of $49,992.00. Following the transaction, the director now owns 5,301 shares in the company, valued at approximately $1,325,037.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Amgen news, Director R Sanders Williams sold 200 shares of the company’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $249.96, for a total value of $49,992.00. Following the completion of the transaction, the director now directly owns 5,301 shares in the company, valued at approximately $1,325,037.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Eckert sold 6,600 shares of the firm’s stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the completion of the sale, the director now directly owns 21,184 shares of the company’s stock, valued at $5,274,816. The disclosure for this sale can be found here. Insiders own 0.46% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on AMGN. Piper Sandler lifted their price target on Amgen from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, August 5th. Royal Bank of Canada upped their price target on Amgen from $224.00 to $236.00 in a research report on Friday, August 5th. Morgan Stanley boosted their price objective on shares of Amgen from $239.00 to $253.00 and gave the company an “equal weight” rating in a research note on Friday, July 15th. Oppenheimer reissued an “outperform” rating and issued a $290.00 price target on shares of Amgen in a report on Wednesday, September 14th. Finally, Atlantic Securities lowered their price objective on Amgen from $190.00 to $182.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $241.13.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.